HB 3799
Creates a method by which a health care practitioner may offer to treat a patient who has a terminal disease or severe chronic disease with an investigational product not approved by the United States Food and Drug Administration.
Official Summary
Digest: The Act allows doctors to give some patients novel types of treatment. (Flesch Readability Score: 74.8). Creates a method by which a health care practitioner may offer to treat a patient who has a terminal disease or severe chronic disease with an investigational product not approved by the United States Food and Drug Administration. Provides protections, including a waiver of liability, for health care practitioners, health care facilities, professional organizations or associations and manufacturers or distributors of investigational products that comply with the Act.
Committee
HBHHC
Sponsors
Rep Bowman
Last Action
In committee upon adjournment.
Invalid Date
Legislative Timeline
House: In committee upon adjournment.
House: Public Hearing held.
House: Referred to Behavioral Health and Health Care.
House: First reading. Referred to Speaker's desk.
Story Thread
4 events tracked · Feb 27 – Jun 27, 2025